Press Releases

LabStyle Innovations Joins College Diabetes Network (CDN)

Dario Smart Diabetes Management Solution to reach thousands of college students across the U.S.

Jul 11, 2016

BOSTONJuly 11, 2016 /PRNewswire/ --

LabStyle Innovations Corp. (NASDAQ: DRIO), developer of the Dario™ Diabetes Management Tool, today announced it has joined the College Diabetes Network (CDN) as a Corporate Member. Since its launch in March 2016, the Dario Smart Diabetes Management Solution - has been shipped to thousands of users across the U.S. who are benefitting from a convenient and easy-to-use tool for managing day-to-day life with diabetes. The CDN Corporate Membership will allow LabStyle to expand its reach to thousands of college students and young adults belonging to the network.

"Smartphones and disruptive app technology have become synonymous with the college student," said Erez Raphael, CEO and Chairman.  "Partnering with a non-profit organization like CDN to connect our ground-breaking, disruptive technology that brings disease management into the digital age with more students and young professionals that manage their lifestyle with diabetes is a natural fit.  As a CDN Corporate Member, we are making our solution and diabetes mobile data lifestyle management application accessible to thousands of college students and young adults across the United States - and connecting them to our growing global user-base."

LabStyle's user-centric engagement via mobile connectivity approach is positioning the company as a major player in the Digital Health space. LabStyle's flagship product, The Dario™ Smart Diabetes Management Solution, is a platform for diabetes management that combines an all-in-one blood glucose meter and a robust, real-time native smartphone app including a wide variety of tools to support and engage users living with diabetes, their doctors and healthcare systems. The Dario has launched in several international markets and most recently in the U.S., the largest market in the world for glucose monitoring.

"We are excited to have LabStyle join CDN as a Corporate Member- and honored to be the first organization they are working with!" said Christina Roth, CEO and Founder of the College Diabetes Network. "LabStyle's technology and Dario product are addressing an important unmet need in the community, simplifying life, leveraging mainstream technology we already carry, and acknowledging the need for blood glucose testing to be more conducive to a person's lifestyle in addition to simply providing clinical information."

The College Diabetes Network serves an important, and unmet, need in the diabetes community. As a Corporate Member, LabStyle looks forward to learning from this hard to reach population, so that the company can continue to develop its platform to best meet their needs. As an organization that relies on the donations of individuals, and the support of companies and foundations, CDN is providing a vital solution for these young adults, while also providing an important service to companies like LabStyle. LabStyle is proud to have its membership not only help it to better meet the needs of its customers, but to also have it be able to be part of a bigger solution for this vulnerable population.

About LabStyle Innovations  

LabStyle Innovations is a leader in digital health self-management solutions. LabStyle delivers the ability to combine and analyze consumer health data to personalize treatment and advance medical knowledge. The Dario™ Smart Diabetes Management Solution is a platform for diabetes management that combines an all-in-one blood glucose meter, native smart phone app, website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.  Having recently launched in the largest market in the world for glucose monitoring, U.S. sales are expected to have a significant impact on revenues and gross margins. With marketing clearance in Europe and the U.S., the Dario iOS mobile app recently launched with reimbursement in the United KingdomAustraliaIsraelItaly, and Canada, and has also launched in New ZealandNetherlandsItaly, and Belgium.  For more information, visit

About the College Diabetes Network (CDN) 

The College Diabetes Network (CDN) is a non-profit organization whose mission is to provide innovative peer based programs which connect and empower students and young professionals to thrive with diabetes. CDN has an extensive network of students across the United States and is the "go-to" hub for everything related to young adulthood and diabetes. The organization also works with campus administrators, pediatric and adult endocrinologists, and parents to better support students in all aspects of their lives. CDN is changing the way people think about and accommodate the needs of young adults living with diabetes. For more information about CDN, visit

Cautionary Note Regarding Forward-Looking Statements  

This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements.  For example, when the Company describes the benefits of the CDN Corporate Membership, and says that U.S. sales are expected to have a significant impact on revenues and gross margins, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For further information: Press Yael Ayalon LabStyle Innovations Corp. +1-800-896-9062 Investor Relations Rob Fink / Brett Maas Hayden IR +1-646-415-8972 / +1-646-536-7331